IL166528A0 - 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors - Google Patents

2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors

Info

Publication number
IL166528A0
IL166528A0 IL16652803A IL16652803A IL166528A0 IL 166528 A0 IL166528 A0 IL 166528A0 IL 16652803 A IL16652803 A IL 16652803A IL 16652803 A IL16652803 A IL 16652803A IL 166528 A0 IL166528 A0 IL 166528A0
Authority
IL
Israel
Prior art keywords
aminoaryl
thiazoles
aryl
amino
kit inhibitors
Prior art date
Application number
IL16652803A
Other languages
English (en)
Original Assignee
Ab Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Science filed Critical Ab Science
Publication of IL166528A0 publication Critical patent/IL166528A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
IL16652803A 2002-08-02 2003-07-31 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors IL166528A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40006402P 2002-08-02 2002-08-02
PCT/IB2003/003685 WO2004014903A1 (fr) 2002-08-02 2003-07-31 2-(3-aminoaryl)amino-4-aryl-thiazoles et leur utilisation en tant que inhibiteurs de c-kit

Publications (1)

Publication Number Publication Date
IL166528A0 true IL166528A0 (en) 2006-01-15

Family

ID=31715693

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16652803A IL166528A0 (en) 2002-08-02 2003-07-31 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors

Country Status (20)

Country Link
US (5) US20050239852A1 (fr)
EP (1) EP1525200B1 (fr)
JP (1) JP4726486B2 (fr)
KR (1) KR101036866B1 (fr)
CN (1) CN100491374C (fr)
AT (1) ATE375342T1 (fr)
BR (1) BRPI0313165B8 (fr)
CA (1) CA2494695C (fr)
CY (1) CY1107036T1 (fr)
DE (1) DE60316810T2 (fr)
DK (1) DK1525200T3 (fr)
ES (1) ES2294344T3 (fr)
HK (1) HK1084382A1 (fr)
IL (1) IL166528A0 (fr)
MX (1) MXPA05001277A (fr)
NO (1) NO330608B1 (fr)
NZ (1) NZ538490A (fr)
PT (1) PT1525200E (fr)
WO (1) WO2004014903A1 (fr)
ZA (1) ZA200501331B (fr)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005507953A (ja) 2001-03-08 2005-03-24 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 抗感染剤としての表面的に両親媒性のポリマー
JP2005500041A (ja) * 2001-06-29 2005-01-06 アブ サイエンス 強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤
DK1401413T3 (da) 2001-06-29 2007-03-26 Ab Science Anvendelse af tyrosinkinaseinhibitorer til behandling af allergiske sygdomme
JP2004537537A (ja) 2001-06-29 2004-12-16 アブ サイエンス 炎症性疾患を治療するためのチロシンキナーゼ阻害剤の使用法
JP3836019B2 (ja) * 2001-11-21 2006-10-18 松下電器産業株式会社 受信装置、送信装置及び送信方法
CN100491374C (zh) 2002-08-02 2009-05-27 Ab科学公司 2-(3-氨基芳基)氨基-4-芳基-噻唑及其作为c-kit抑制剂的应用
US8450302B2 (en) * 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
WO2004076693A1 (fr) * 2003-02-27 2004-09-10 Ab Science Traitement individualise pour differentes formes de mastocytose
KR101241176B1 (ko) 2003-03-17 2013-03-13 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 표면적으로 양쪽성인 중합체 및 올리고머 및 이의 용도
US20070191267A1 (en) * 2003-04-28 2007-08-16 Ab Science Use of tyrosine kinase inhibitors for treating cerebral ischemia
JP2007502809A (ja) * 2003-08-15 2007-02-15 アブ サイエンス ＩＩ型糖尿病を治療するためのｃ−ｋｉｔ阻害剤の使用方法
BRPI0418074B8 (pt) * 2003-12-25 2021-05-25 Nippon Shinyaku Co Ltd derivado de amida, composição farmacêutica, inibidor da tirosina cinase bcr-abl e agentes terapêuticos
WO2005072246A2 (fr) 2004-01-23 2005-08-11 The Trustees Of The University Of Pennsylvania Polymeres et oligomeres de polyaryle et de polyarylalkynyle amphiphiles au niveau facial
NZ548884A (en) * 2004-01-30 2010-06-25 Ab Science 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
CA2567574C (fr) * 2004-04-08 2013-01-08 Targegen, Inc. Inhibiteurs benzotriazine de kinases
US20080146585A1 (en) * 2004-04-20 2008-06-19 Ab Science Use Of C-Kit Inhibitors For Treating Inflammatory Muscle Disorders Including Myositis And Muscular Dystrophy
WO2005102318A1 (fr) * 2004-04-20 2005-11-03 Ab Science Utilisation d'inhibiteurs de c-kit dans le traitement des maladies liees au vih
WO2005102326A2 (fr) * 2004-04-23 2005-11-03 Ab Science Utilisation d'inhibiteurs de c-kit dans le traitement des maladies renales
EP1742633A2 (fr) * 2004-04-23 2007-01-17 AB Science Utilisation des inhibiteurs de c-kit pour le traitement de la fibrose
WO2005111007A1 (fr) 2004-05-17 2005-11-24 Otsuka Pharmaceutical Co., Ltd. Composé thiazole et utilisation de celui-ci
EP1746990A1 (fr) * 2004-05-18 2007-01-31 AB Science Utilisation d'inhibiteurs de mastocytes dans le traitement de patients exposes a des armes chimiques ou biologiques
WO2005115304A2 (fr) * 2004-05-24 2005-12-08 Ab Science Utilisation d'inhibiteurs de c-kit pour le traitement de la fibrodysplasie
WO2005115385A1 (fr) * 2004-05-24 2005-12-08 Ab Science Utilisation d'inhibiteurs de c-kit pour le traitement de l'acne
CA2578283A1 (fr) 2004-08-25 2006-03-02 Targegen, Inc. Composes heterocycliques et methodes d'utilisation
WO2006093813A2 (fr) * 2005-02-25 2006-09-08 THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA et al. Polymeres et oligomeres a faces amphiphiles, composition a base de ceux-ci et, leur utilisation dans des procedes de traitement du cancer
US8088806B2 (en) 2005-05-09 2012-01-03 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
WO2006133411A1 (fr) * 2005-06-08 2006-12-14 Targegen, Inc. Methodes et preparations pour le traitement de troubles oculaires
GB0512091D0 (en) * 2005-06-14 2005-07-20 Novartis Ag Organic compounds
US20080207572A1 (en) * 2005-07-14 2008-08-28 Ab Science Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma
JP2009506125A (ja) * 2005-08-29 2009-02-12 ジェラルド・エム・ハウシー セラミューテイン・モジュレーター
US8133900B2 (en) * 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
BRPI0618179A2 (pt) * 2005-11-01 2011-08-23 Targegen Inc inibidores de biaril meta pirimidina de cinases
KR100716891B1 (ko) * 2005-11-01 2007-05-09 (주)아모레퍼시픽 피리딘 티아졸 카복사마이드 유도체, 이의 제조방법 및이를 함유하는 피부 미백용 조성물
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US20070161645A1 (en) * 2005-11-02 2007-07-12 Targegen, Inc. Thiazole inhibitors targeting resistant kinase mutations
US20070135368A1 (en) * 2005-12-09 2007-06-14 Knapp Pamela E Cell-to-cell transmission of siRNA induced gene silencing in mammalian cells
WO2007076460A2 (fr) * 2005-12-23 2007-07-05 Kalypsys, Inc. Nouveaux thiazole-urees substitues utiles en tant qu'inhibiteurs de proteine-kinases
DE102005062986A1 (de) 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte Propiolsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln
DE102005062990A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte Thiazole und ihre Verwendung zur Herstellung von Arzneimitteln
CA2649755C (fr) * 2006-04-20 2014-12-02 Janssen Pharmaceutica N.V. Procede d'inhibition de la kinase de c-kit
US8030487B2 (en) 2006-07-07 2011-10-04 Targegen, Inc. 2-amino—5-substituted pyrimidine inhibitors
ES2606505T3 (es) 2007-01-12 2017-03-24 Ab Science Tratamiento de combinación de cánceres sólidos con antimetabolitos e inhibidores de tirosina quinasa
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
JP5568312B2 (ja) * 2007-02-13 2014-08-06 アーべー・シオンス キナーゼ阻害剤としての２−アミノチアゾール化合物の合成方法
EP1964848A1 (fr) * 2007-03-01 2008-09-03 Bayer Schering Pharma Aktiengesellschaft Procédés de radiofluoration
BRPI0811939A2 (pt) 2007-05-22 2014-11-25 Achillion Pharmaceuticals Inc Tiazóis substituídos por heteroarila
KR100885692B1 (ko) * 2007-06-12 2009-02-26 한국화학연구원 2-(3-클로로-4-메톡시)아닐리노-4-아릴싸이아졸 유도체또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및이를 유효성분으로 함유하는 암 예방 및 치료용 약학적조성물
MX2010004718A (es) * 2007-11-01 2010-07-28 Acucela Inc Compuestos derivados de amina para tratar enfermedades y trastornos oftalmicos.
FR2928150A1 (fr) * 2008-02-29 2009-09-04 Vetoquinol Sa Sa Nouveaux derives 7-substitues de 3-carboxy-oxadiazino-quinolones, leur preparation et leur application comme anti-bacteriens
US8106209B2 (en) 2008-06-06 2012-01-31 Achillion Pharmaceuticals, Inc. Substituted aminothiazole prodrugs of compounds with anti-HCV activity
EP2145891A1 (fr) * 2008-07-09 2010-01-20 Vetoquinol S.A. Dérivés de 9-substitués-5-carboxy-oxadiazino-quinolone, leur préparation et leur application en tant qu'antibactériens
CN102421430B (zh) * 2009-04-06 2014-06-25 纽若泰克制药株式会社 用于预防或治疗烧伤的药物组合物
US20120302577A1 (en) * 2010-01-28 2012-11-29 Ab Science Treatment of gist with masitinib
TW201130830A (en) 2010-02-01 2011-09-16 Ab Science Combined treatment of pancreatic cancer with gemcitabine and masitinib
AR080380A1 (es) * 2010-03-09 2012-04-04 Ab Science Tratamiento de la demencia tipo alzheimer con masitinib
DE102010012594A1 (de) 2010-03-23 2011-09-29 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an einem oder mehreren Thiazolderivaten
TW201204360A (en) 2010-04-20 2012-02-01 Ab Science Treatment of multiple sclerosis with MASITINIB
TW201204719A (en) 2010-06-02 2012-02-01 Ab Science Treatment of rheumatoid arthritis with masitinib
US10045978B2 (en) 2010-11-05 2018-08-14 Ab Science Treatment of mastocytosis with masitinib
US20140147415A1 (en) * 2010-11-05 2014-05-29 Ab Science Treatment of mastocytosis with masitinib
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
US9078894B2 (en) * 2011-02-04 2015-07-14 Ab Science Treatment of severe persistant asthma with masitinib
EP2680846A4 (fr) * 2011-03-01 2014-08-06 Npharmakon Llc Utilisation de n-(4-méthoxyphényl)-1-phényl-1h-pyrazol-3-amine et composés associés
WO2012136732A1 (fr) 2011-04-08 2012-10-11 Ab Science Traitement du myélome multiple au moyen de mastinib
EP2736904B1 (fr) 2011-07-27 2016-03-16 AB Science Derives d'oxazole et thiazole en tant qu'inhibiteurs selectifs de proteine kinase (c-kit)
CN103130791B (zh) * 2011-11-30 2016-05-04 正大天晴药业集团股份有限公司 一种新型苯甲酰胺类化合物
CN103130792B (zh) * 2011-11-30 2016-05-04 正大天晴药业集团股份有限公司 一种2-氨基噻唑类化合物
WO2014053650A1 (fr) 2012-10-04 2014-04-10 Ab Science Utilisation de masitinib pour le traitement du cancer chez des sous-populations de patients identifiées à l'aide de facteurs de prédiction
TW201534597A (zh) * 2013-06-20 2015-09-16 Ab Science 作為選擇性蛋白質激酶抑制劑之苯并咪唑衍生物
USD704961S1 (en) 2013-07-03 2014-05-20 Wearwell Studded molded mat
WO2015082496A1 (fr) 2013-12-02 2015-06-11 Ab Science Utilisation de masitinib pour le traitement du cancer colorectal
EP2886543A1 (fr) 2013-12-18 2015-06-24 Sandoz Ag Forme cristalline de masitinibe
WO2015185958A1 (fr) 2014-06-02 2015-12-10 Ab Science Utilisation d'un inhibiteur de l'activité kinase, en particulier le masitinib, pour le traitement du cancer de la prostate
CN104045632B (zh) * 2014-06-03 2016-09-07 辽宁大学 抗肿瘤药物苯并二氢吡喃（噻喃）酰胺类化合物及其药学上可接受的盐及制备方法和应用
US20160175302A1 (en) * 2014-12-17 2016-06-23 Ab Science Masitinib for treating gastric cancer
ES2796276T3 (es) * 2015-02-05 2020-11-26 Ab Science Compuestos con actividad antitumoral
CN106794179A (zh) * 2015-07-29 2017-05-31 苏州晶云药物科技有限公司 马赛替尼甲磺酸盐的新晶型及其制备方法
CA3000894A1 (fr) 2015-10-05 2017-04-13 Ab Science Traitement de la mastocytose systemique grave par le masitinib
HUE057398T2 (hu) 2016-03-25 2022-05-28 Ab Science A masitinib alkalmazása egy amiotrófiás laterálszklerózisos beteg alpopuláció kezelésére
EP3601278B1 (fr) 2017-03-31 2022-10-26 Sandoz AG Forme cristalline de masitinibe
CN108721283A (zh) * 2017-04-20 2018-11-02 华东理工大学 噻唑衍生物在治疗非淋巴细胞性白血病中的应用
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021099616A1 (fr) 2019-11-22 2021-05-27 Ab Science Masitinib pour le traitement de la drépanocytose
EP3831384A1 (fr) 2019-12-02 2021-06-09 AB Science Utilisation de masitinib pour le traitement de l'asthme éosinophile
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
KR20220143020A (ko) 2020-02-20 2022-10-24 에이비 사이언스 다발 경화증 환자 하위집단의 치료를 위한 마시티닙
US20230226043A1 (en) 2020-04-10 2023-07-20 Ab Science Use of masitinib for the treatment of coronavirus disease 2019 (covid-19)
CA3201259A1 (fr) 2020-12-16 2022-06-23 Alain Moussy Masitinib pour le traitement de la maladie d'alzheimer
IL308088A (en) 2021-05-17 2023-12-01 Ab Science Mestitinib for the treatment of castrate-resistant prostate cancer
WO2023081923A1 (fr) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Inhibiteurs du récepteur du facteur de croissance dérivé des plaquettes (pdgfr) alpha et leurs utilisations
CN114644582B (zh) * 2022-04-11 2024-03-29 中原工学院 一种苯基双硫脲类化合物的制备方法

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US590622A (en) * 1897-09-28 Edward mcconnell
US3192225A (en) * 1961-04-24 1965-06-29 Geigy Chem Corp 2-substituted aminothiazoles
US3467666A (en) * 1966-11-07 1969-09-16 Geigy Chem Corp 2-substituted aminothiazoles
US3740420A (en) * 1967-11-28 1973-06-19 Crown Zellerbach Corp Pharmaceutical compositions with dimethyl sulfoxide
FR2077803B1 (fr) * 1970-02-16 1973-03-16 Innothera Lab Sa
US3743727A (en) * 1970-11-16 1973-07-03 Crown Zellerbach Corp Enhancing tissue penetration of certain antimicrobial agents with dimethyl sulfoxide
US4405616A (en) * 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US3989816A (en) * 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4343940A (en) * 1979-02-13 1982-08-10 Mead Johnson & Company Anti-tumor quinazoline compounds
CA1163561A (fr) * 1979-11-06 1984-03-13 Cyril Boroda Preparation contenant de la nitroglycerine et parfois d'autres medicaments et methode de preparation
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4460372A (en) * 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4411893A (en) * 1981-08-14 1983-10-25 Minnesota Mining And Manufacturing Company Topical medicament preparations
JPS5968336U (ja) 1982-10-28 1984-05-09 シャープ株式会社 原稿カバ−開閉検出装置
CA1236029A (fr) * 1984-05-14 1988-05-03 Edmund Sandborn Solutions pharmaceutiques contenant du dimethylsulfoxyde
US4615699A (en) * 1985-05-03 1986-10-07 Alza Corporation Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes
JPS6328447A (ja) 1986-07-21 1988-02-06 Toshiba Corp 加速管
JP2752361B2 (ja) 1986-11-03 1998-05-18 エバレディー、バッテリー、カンパニー、インコーポレーテッド 正極端子ピンと過塩素酸塩電解質を有する密閉された非水性電池
US5217999A (en) * 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE3815221C2 (de) * 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
GB9413975D0 (en) * 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
CA2078214C (fr) 1990-04-02 1995-03-28 Robert Lee Dow Inhibiteur de tyrosine kinase a base d'acide phenylmethanephosphonique
US5302606A (en) * 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US5714493A (en) * 1991-05-10 1998-02-03 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
ES2108120T3 (es) 1991-05-10 1997-12-16 Rhone Poulenc Rorer Int Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
JP2549583B2 (ja) 1991-05-10 1996-10-30 明成化学工業株式会社 セルロース繊維の反応染色における未固着染料の退色防止法
US6194439B1 (en) 1991-05-29 2001-02-27 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
TW225528B (fr) * 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
HUT71553A (en) 1992-08-06 1995-12-28 Warner Lambert Co 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US5330992A (en) * 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5656643A (en) * 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US6239172B1 (en) * 1997-04-10 2001-05-29 Nitrosystems, Inc. Formulations for treating disease and methods of using same
JP3728770B2 (ja) 1995-06-01 2005-12-21 ブラザー工業株式会社 原稿読取り装置
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5906202A (en) 1996-11-21 1999-05-25 Aradigm Corporation Device and method for directing aerosolized mist to a specific area of the respiratory tract
US5776020A (en) * 1997-05-19 1998-07-07 Barone; Michael A. Tensioning device for sporting racquets
US5883166A (en) * 1997-06-26 1999-03-16 Jennings; Thomas C. Liquid internal mold release agents for unsaturated polyester thermosetting molding compounds
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
JP4333676B2 (ja) 1997-11-21 2009-09-16 オムロン株式会社 プログラム制御装置、プログラム制御方法、およびプログラム記録媒体
US6291514B1 (en) * 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
EP1137415A4 (fr) * 1998-12-07 2002-03-20 Smithkline Beecham Corp Inhibiteurs de la myt1 kinase
JP2002533360A (ja) 1998-12-31 2002-10-08 スージェン・インコーポレーテッド 蛋白質キナーゼ活性を調節するためおよび癌の化学療法において用いるための３−ヘテロアリーリデニル−２−インドリノン化合物
UA71971C2 (en) * 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
ATE414079T1 (de) 2000-03-01 2008-11-15 Janssen Pharmaceutica Nv 2,4-disubstituierte thiazolyl derivate
US7087608B2 (en) 2000-03-03 2006-08-08 Robert Charles Atkins Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
US6586453B2 (en) * 2000-04-03 2003-07-01 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
US6892245B1 (en) 2000-09-22 2005-05-10 Nortel Networks Limited Management information base for a multi-domain network address translator
JP2002185796A (ja) 2000-12-11 2002-06-28 Canon Inc 画像読取処理システムおよび画像読取処理方法、並びに記録媒体
ITTO20010110A1 (it) * 2001-02-08 2002-08-08 Rotta Research Lab Nuovi derivati benzamidinici dotati di attivita' anti-infiammatoria ed immunosoppressiva.
GB0108606D0 (en) 2001-04-05 2001-05-23 Novartis Ag Organic compounds
EP1260876B1 (fr) 2001-05-25 2013-05-22 Ricoh Company, Ltd. Couvercle pour la plaque d'exposition, dispositif de balayage d'images et dispositif de formation d'images avec le couvercle
ATE343415T1 (de) 2001-06-29 2006-11-15 Ab Science Die verwendung von c-kit hemmer zur behandlung von entzündlichen darmerkrankungen
WO2003002105A2 (fr) 2001-06-29 2003-01-09 Ab Science Utilisation d'inhibiteurs de la tyrosine kinase dans le traitement de la perte osseuse
JP2004537537A (ja) 2001-06-29 2004-12-16 アブ サイエンス 炎症性疾患を治療するためのチロシンキナーゼ阻害剤の使用法
EP1471907B1 (fr) 2001-06-29 2008-07-16 AB Science Utilisation d'inhibiteurs de c-kit destines a traiter des maladies auto-immunes
US20050054617A1 (en) 2001-06-29 2005-03-10 Alain Moussy Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis
JP2005500041A (ja) 2001-06-29 2005-01-06 アブ サイエンス 強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤
DK1401413T3 (da) 2001-06-29 2007-03-26 Ab Science Anvendelse af tyrosinkinaseinhibitorer til behandling af allergiske sygdomme
JP2005502614A (ja) 2001-06-29 2005-01-27 アブ サイエンス 多発性硬化症（ｍｓ）を治療するためのチロシンキナーゼ阻害剤の使用方法
EP1401412A2 (fr) 2001-06-29 2004-03-31 AB Science Utilisation d'inhibiteurs de materiel c, puissants, selectifs et non toxiques pour traiter l'angiogenese tumorale
US20030091974A1 (en) 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
WO2003039550A1 (fr) 2001-09-20 2003-05-15 Ab Science Utilisation d'inhibiteurs de tyrosine kinase pour blanchir la peau humaine et traiter des troubles associes a un dysfonctionnement des melanocytes
US20040241226A1 (en) 2001-09-20 2004-12-02 Alain Moussy Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections
ATE401078T1 (de) 2001-09-20 2008-08-15 Ab Science Die verwendung von c-kithemmern zur förderung des haarwuchses
JP2003134307A (ja) 2001-10-26 2003-05-09 Canon Inc 画像読取装置
US20030158199A1 (en) * 2002-01-25 2003-08-21 Kylix, B.V. Novel compounds for inhibition of Tie-2
CA2474322A1 (fr) 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. (thia-/oxa-/pyra) zoles substitues 4(hetero-) aryle pour inhibition de tie-2
CN100491374C (zh) * 2002-08-02 2009-05-27 Ab科学公司 2-(3-氨基芳基)氨基-4-芳基-噻唑及其作为c-kit抑制剂的应用
JP5568312B2 (ja) 2007-02-13 2014-08-06 アーべー・シオンス キナーゼ阻害剤としての２−アミノチアゾール化合物の合成方法

Also Published As

Publication number Publication date
JP2005539021A (ja) 2005-12-22
US20080255141A1 (en) 2008-10-16
US20050239852A1 (en) 2005-10-27
CY1107036T1 (el) 2012-09-26
JP4726486B2 (ja) 2011-07-20
DE60316810D1 (de) 2007-11-22
US7423055B2 (en) 2008-09-09
BRPI0313165B1 (pt) 2019-01-29
US20140088108A1 (en) 2014-03-27
WO2004014903A1 (fr) 2004-02-19
EP1525200B1 (fr) 2007-10-10
BR0313165A (pt) 2005-06-14
CA2494695A1 (fr) 2004-02-19
PT1525200E (pt) 2008-01-10
ZA200501331B (en) 2005-11-30
NZ538490A (en) 2006-12-22
KR20050038010A (ko) 2005-04-25
DK1525200T3 (da) 2007-12-03
DE60316810T2 (de) 2008-07-17
EP1525200A1 (fr) 2005-04-27
MXPA05001277A (es) 2005-10-06
NO20051115L (no) 2005-03-02
HK1084382A1 (en) 2006-07-28
US8835435B2 (en) 2014-09-16
ES2294344T3 (es) 2008-04-01
CA2494695C (fr) 2011-04-05
ATE375342T1 (de) 2007-10-15
CN100491374C (zh) 2009-05-27
CN1684959A (zh) 2005-10-19
US8993573B2 (en) 2015-03-31
KR101036866B1 (ko) 2011-05-25
US20040110810A1 (en) 2004-06-10
NO330608B1 (no) 2011-05-23
BRPI0313165B8 (pt) 2021-05-25
US20120053186A1 (en) 2012-03-01
AU2003253195A1 (en) 2004-02-25

Similar Documents

Publication Publication Date Title
ZA200501331B (en) 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
BRPI0415467A (pt) compostos de 2-aminoariloxazol para o tratamento de doenças
UA95071C2 (ru) Замещенные производные оксазола и их применение как ингибиторов тирозинкиназы
NO20063861L (no) 2-(3-substituert aryl)amin-4-arylthiazoler som tyrosinkinasehemmere
WO2006064375A2 (fr) Composes heterocycliques a noyau a cinq elements a substitution aminoaryle pour le traitement de maladies
NO20075627L (no) Inhibitorer av cytosolisk fosfolipase A2
ATE381332T1 (de) Tyrosinkinase-hemmer
CY1110663T1 (el) 2-αμινοαρυλοξαζολικες ενωσεις ως παρεμποδιστες κινασων της τυροσινης
WO2007013896A3 (fr) Composes modulant l'activite de c-kit et c-fms et utilisations
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
WO2004089286A3 (fr) Nouveaux composes et compositions utilises comme inhibiteurs de la proteine kinase
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
MXPA05013224A (es) Piridinilcarbamatos como inhibidores de lipasa sensible a hormonas.
DE60315146D1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
IL192557A (en) Imidazole derivatives are conserved and used as ptpase inhibitors
DK1401415T3 (da) Anvendelse af N-phenyl-2-pyrimidinamin-derivater til behandling af inflammatoriske sygdomme
ATE334693T1 (de) Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheiten
ATE494008T1 (de) Verwendung eines p38-kinasehemmers zur behandlung von psychiatrischen erkrankungen
CU20070222A7 (es) Derivados de oxazol sustituidos y su uso como inhibidores de tirosina quinasa

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed